<DOC>
	<DOCNO>NCT02269813</DOCNO>
	<brief_summary>PRIMe prospective , case-only trial design measure impact MammaPrint physician chemotherapy intention two discordant group ( ET/POOR , CT/GOOD ) stage 1 2 HR-positive HER2-negative breast cancer patient . The design also provide assessment several important secondary indicator . Eligible patient tumor sample analyze MammaPrint , BluePrint TargetPrint . Patients start treatment MammaPrint result receive take consideration adjuvant treatment plan .</brief_summary>
	<brief_title>PRospective Study Measure Impact MammaPrint Adjuvant Treatment Hormone Receptor-positive HER2-negative Breast Cancer Patients ( PRIMe )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Women histologically proven invasive stage 1 2 breast cancer Hormone receptor positive accord local standard HER2 negative i.e . IHC 01+ , FISH ISH nonamplified ( locally assess ) Axillary lymph node status : 03 involve ( macro metastasis i.e . &gt; 2mm OR micro metastasis i.e . &gt; 0.22mm ) ≥ 18 year age time consent Patients must eligible receive adjuvant chemotherapy endocrine therapy define good Karnofsky index , hematological , cardiological hepatic contraindication impede comorbidity Written inform consent ≥4 involve axillary node Multicentric disease 2 clinically relevant lesion HR negative OR HER2 positive/amplified ( locally assess ) Previous diagnosis malignancy unless disease free 10 year Metastatic disease Tumor sample ship Agendia ≤ 30 % tumor cell fail QA QC criterion Women start complete adjuvant chemotherapy neoadjuvant chemotherapy current breast cancer</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>MammaPrint</keyword>
	<keyword>BluePrint</keyword>
	<keyword>TargetPrint</keyword>
</DOC>